Literature DB >> 22025145

High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer.

Luka Ozretić, Kerstin Rhiem, Sebastian Huss, Barbara Wappenschmidt, Birgid Markiefka, Peter Sinn, Rita K Schmutzler, Reinhard Buettner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22025145     DOI： 10.1200/JCO.2011.38.1988

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

Authors:  Heidrun Gevensleben; Verena Bossung; Alfons Meindl; Barbara Wappenschmidt; Nikolaus de Gregorio; Ana Osorio; Atocha Romero; Reinhard Buettner; Birgid Markiefka; Rita Katharina Schmutzler
Journal:  Virchows Arch       Date:  2014-07-04       Impact factor: 4.064

2.  PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.

Authors:  Samuel Sander Effron; Mehran Makvandi; Lilie Lin; Kuiying Xu; Shihong Li; Hsiaoju Lee; Catherine Hou; Daniel A Pryma; Cameron Koch; Robert H Mach
Journal:  Cancer Biother Radiopharm       Date:  2017-01-24       Impact factor: 3.099

3.  Nuclear PARP1 expression and its prognostic significance in breast cancer patients.

Authors:  Annalisa Mazzotta; Giulia Partipilo; Simona De Summa; Francesco Giotta; Giovanni Simone; Anita Mangia
Journal:  Tumour Biol       Date:  2015-11-27

4.  Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.

Authors:  Marie-Luise Klauke; Nicoline Hoogerbrugge; Jan Budczies; Peter Bult; Judith Prinzler; Cornelia Radke; J Han J M van Krieken; Manfred Dietel; Carsten Denkert; Berit Maria Müller
Journal:  Virchows Arch       Date:  2012-09-12       Impact factor: 4.064

5.  Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.

Authors:  Lili Zhai; Shuai Li; Huilan Li; Yi Zheng; Ronggang Lang; Yu Fan; Feng Gu; Xiaojing Guo; Xinmin Zhang; Li Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

6.  Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.

Authors:  Miriam Deniz; Tatiana Romashova; Sarah Kostezka; Anke Faul; Theresa Gundelach; Maria Moreno-Villanueva; Wolfgang Janni; Thomas W P Friedl; Lisa Wiesmüller
Journal:  Oncotarget       Date:  2017-10-09

7.  A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.

Authors:  Mehran Makvandi; Kuiying Xu; Brian P Lieberman; Redmond-Craig Anderson; Samuel Sander Effron; Harrison D Winters; Chenbo Zeng; Elizabeth S McDonald; Daniel A Pryma; Roger A Greenberg; Robert H Mach
Journal:  Cancer Res       Date:  2016-06-03       Impact factor: 13.312

8.  BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.

Authors:  William Jacot; Simon Thezenas; Romain Senal; Cathy Viglianti; Anne-Claire Laberenne; Evelyne Lopez-Crapez; Frédéric Bibeau; Jean-Pierre Bleuse; Gilles Romieu; Pierre-Jean Lamy
Journal:  BMC Cancer       Date:  2013-11-05       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.